Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma

por Orlowski, Robert Z.
Publicado 2018

Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?

por Ray, Upasana, Orlowski, Robert Z.
Publicado 2023

The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

por Orlowski, Robert Z, Dees, E Claire
Publicado 2003

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma

por Shah, Jatin J, Orlowski, Robert Z, Thomas, Sheeba K
Publicado 2009

Bayesian Joint Selection of Genes and Pathways: Applications in Multiple Myeloma Genomics

por Zhang, Lin, Morris, Jeffrey S, Zhang, Jiexin, Orlowski, Robert Z, Baladandayuthapani, Veerabhadran
Publicado 2014

Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma

por Zhang, Yu, Zhou, Liang, Leng, Yun, Dai, Yun, Orlowski, Robert Z., Grant, Steven
Publicado 2017

Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma

por Wang, Xiaobin, Shirazi, Fazal, Yan, Wei, Liu, Xiaoyu, Wang, Hua, Orlowski, Robert Z., Wang, Huihan
Publicado 2021

Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()

por Zaman, Shadia, Shentu, Shujun, Yang, Jing, He, Jin, Orlowski, Robert Z., Stellrecht, Christine M., Gandhi, Varsha
Publicado 2015

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat

por Cheng, Tiewei, Kiser, Kendall, Grasse, Leslie, Iles, Lakesla, Bartholomeusz, Geoffrey, Samaniego, Felipe, Orlowski, Robert Z., Chandra, Joya
Publicado 2021

Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in mul...

por Wang, Hua, Baladandayuthapani, Veerabhadran, Wang, Zhiqiang, Lin, Heather, Berkova, Zuzana, Davis, Richard E., Yang, Lin, Orlowski, Robert Z.
Publicado 2017

PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYEL...

por Ferreri, Christopher J., Quatela, Steven, Aina, Oluwaseun, Roy, Pourab, Boyapati, Anita, Lorenc, Karen Rodriguez, Kroog, Glenn, Orlowski, Robert Z
Publicado 2023

Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes

por Purushothaman, Anurag, Bandari, Shyam K., Chandrashekar, Darshan S., Jones, Richard J., Lee, Hans C., Weber, Donna M., Orlowski, Robert Z.
Publicado 2017

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo

por Zhou, Liang, Zhang, Yu, Sampath, Deepak, Leverson, Joel, Dai, Yun, Kmieciak, Maciej, Nguyen, Matthew, Orlowski, Robert Z, Grant, Steven
Publicado 2018

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

por Cadieux, Benoit, Coleman, Robert, Jafarinasabian, Pegah, Lipton, Allan, Orlowski, Robert Z., Saad, Fred, Scagliotti, Giorgio V., Shimizu, Kazuyuki, Stopeck, Alison
Publicado 2022

Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies

por Torres, Harrys A., Angelidakis, Georgios, Jiang, Ying, Economides, Minas, Mustafayev, Khalis, Yibirin, Marcel, Orlowski, Robert, Champlin, Richard, Verstovsek, Srdan, Raad, Issam
Publicado 2022

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

por Makker, Vicky, Taylor, Matthew H., Oaknin, Ana, Casado Herraez, Antonio, Orlowski, Robert, Dutta, Lea, Ren, Min, Zale, Melissa, O'Malley, David M.
Publicado 2021

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023

por Mateos, Maria-Victoria, Siegel, David, Shah, Jatin J, Reece, Donna, Avigan, David, Orlowski, Robert, Ge, Yang, Balakumaran, Arun, Marinello, Patricia, Miguel, Jesus San
Publicado 2015

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with b...

por Buda, Gabriele, Ricci, Deborah, Huang, C. Chris, Favis, Reyna, Cohen, Nadine, Zhuang, Sen H., Harousseau, Jean-Luc, Sonneveld, Pieter, Bladé, Joan, Orlowski, Robert Z.
Publicado 2010

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434

por Srkalovic, Gordan, Hussein, Mohamad A, Hoering, Antje, Zonder, Jeffrey A, Popplewell, Leslie L, Trivedi, Harsha, Mazzoni, Sandy, Sexton, Rachel, Orlowski, Robert Z, Barlogie, Bart
Publicado 2014

Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737

por Gu, Dongmin, Wang, Shuhong, Kuiatse, Isere, Wang, Hua, He, Jin, Dai, Yun, Jones, Richard J., Bjorklund, Chad C., Yang, Jing, Grant, Steven, Orlowski, Robert Z.
Publicado 2014